Core Viewpoint - China National Pharmaceutical Group Corporation plans to acquire 100% equity of Beijing Jinsui Technology Development Co., Ltd. from China Emerging Group for a cash consideration of 302.07 million yuan, enhancing its marketing capabilities and supply chain management in the pharmaceutical and health product sectors [2][4]. Summary by Sections 1. Overview of Related Transactions - The acquisition involves a cash payment of 302.07 million yuan for the 100% equity of Jinsui Technology, which will become a wholly-owned subsidiary of China National Pharmaceutical [2][4]. - This transaction is classified as a related party transaction due to the relationship between China Emerging Group and the company [2][5]. 2. Related Party Information - China Emerging Group is a wholly-owned subsidiary of China General Technology (Group) Holding, which is the controlling shareholder of China National Pharmaceutical [5][6]. 3. Financial Data of Jinsui Technology - As of March 31, 2025, Jinsui Technology reported total assets of 890.17 million yuan and net assets of 224.54 million yuan, with revenue of 264.43 million yuan and net profit of 6.24 million yuan for the first quarter [15]. - The company has experienced a decline in revenue due to business restructuring and is actively seeking to optimize its product structure [15][12]. 4. Valuation and Pricing of the Transaction - The valuation of Jinsui Technology was conducted using both asset-based and income approaches, with the income approach yielding a valuation of 302.07 million yuan, reflecting a significant premium over the book value [20][22]. - The transaction price was agreed upon based on the valuation report, ensuring fairness and reasonableness [23][32]. 5. Impact of the Transaction on the Company - The acquisition is expected to strengthen the company's e-commerce operations and marketing strategies, facilitating its transition from a pharmaceutical company to a health enterprise [30][31]. - The integration of Jinsui Technology's resources and expertise is anticipated to enhance the company's capabilities in the health product sector [30][31]. 6. Approval Process - The transaction was approved by the board of directors, with independent directors affirming that it aligns with the company's strategic direction and does not harm the interests of minority shareholders [38][39].

Mergers and Acquisitions - China Medical plans to acquire 100% equity of Jinsui Technology for 302 million yuan, with Jinsui's core business being e-commerce operations and brand authorization for Philips personal health products [1] - Sunshine Nuohuo intends to purchase 100% equity of Jiangsu Langyan Life Science Technology through share issuance and convertible bonds, focusing on high-end chemical drugs and providing pharmaceutical production services [2] - Yunnan Copper is planning to acquire 40% equity of Liangshan Mining from its parent company, with the stock suspension expected to last no more than 10 trading days [3] Share Buybacks and Increases - Haizheng Pharmaceutical intends to repurchase shares worth between 50 million and 100 million yuan for an employee stock ownership plan, with a maximum repurchase price of 13 yuan per share [4] - Tianqiao Hoisting's controlling shareholder plans to increase holdings between 75 million and 150 million yuan, with a maximum purchase price of 5 yuan per share [5] - China Railway Industry's controlling shareholder plans to increase holdings between 160 million and 300 million yuan, with a limit of 2% of the total share capital [6] Stock Market Activity - Chunguang Technology's stock has seen a significant increase of 59.76% over six trading days, indicating potential irrational market speculation [7] - Lijun Co. confirms normal operations and no undisclosed significant matters despite stock price fluctuations exceeding 20% [8][9] - Tongwei Co. executives plan to reduce their holdings by a total of 22,200 shares due to personal financial needs, representing 0.1016% of the total share capital [10]

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...

4.央行等联合印发《关于金融支持广州南沙深化面向世界的粤港澳全面合作的意见》 近日，中国人民银行、金融监管总局、中国证监会、国家外汇局、广东省人民政府联合印发《关于金融 支持广州南沙深化面向世界的粤港澳全面合作的意见》（以下简称《意见》）。《意见》从完善创新创 业金融服务、加强社会民生领域金融服务、发展特色金融服务、推进粤港澳金融市场互联互通、开展跨 境金融创新与交流、完善金融监管机制等方面提出30条重点举措，推动广州南沙在粤港澳大湾区"新发 展格局战略支点、高质量发展示范地、中国式现代化引领地"建设中更好发挥引领带动作用。 5.广东发布《金融支持促消费扩内需专项行动方案》 重要的消息有哪些 1.中美日内瓦经贸会谈联合声明 双方承诺将于2025年5月14日前采取以下举措：美国将（一）修改2025年4月2日第14257号行政令中规定 的对中国商品（包括香港特别行政区和澳门特别行政区商品）加征的从价关税，其中，24%的关税在初 始的90天内暂停实施，同时保留按该行政令的规定对这些商品加征剩余10%的关税；（二）取消根据 2025年4月8日第14259号行政令和2025年4月9日第14266号行政令对这些商品的加征 ...

Company Announcements - Zhaowei Electromechanical plans to reduce its shareholding by no more than 1.5%, equating to approximately 3.6 million shares [1] - China CNR Corporation has signed several major contracts totaling approximately 54.74 billion yuan, representing about 22.2% of its expected revenue for 2024 [2] - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a temporary suspension of its stock [2] - Sunshine Nuohua intends to acquire 100% of Langyan Life, with its stock set to resume trading [3] - Wolong Materials is planning to issue H-shares and apply for a listing on the Hong Kong Stock Exchange [3] - Hanyu Pharmaceutical has signed a joint development agreement for a novel peptide drug targeting metabolic diseases [3] - Lijun Co. confirms that its operations are normal and there are no undisclosed significant matters [3] Investments & Acquisitions - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [4] - Shuangyi Technology intends to acquire 100% of Marky Industries for 18 million AUD, along with specific assets [5] Strategic Partnerships - Sileck has signed a strategic cooperation agreement with Lihua Power for the development of large cylindrical batteries [6] - Hongchang Technology plans to invest 15 million yuan in a humanoid robot industry chain company [7] - Macroview Technology is establishing a wholly-owned subsidiary focused on artificial intelligence [8] - Yihua Jiaye has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health to develop a sleep health ecosystem [9] - Wanda Film is investing in Lezi Tiancheng and will engage in strategic cooperation in IP toy product development [10] Shareholding Changes - Tiandi Online's controlling shareholder is transferring 6.97% of its shares to introduce a strategic investor [12] - Longjiang Transportation plans to reduce its shareholding by no more than 3% [13] - Boyun New Materials intends to reduce its shareholding by no more than 3% [14] - Tongrun Equipment's major shareholder plans to reduce its stake by no more than 2% [15] Financing & Capital Increase - Tangyuan Electric plans to raise no more than 864 million yuan through a private placement [16] - Shangsheng Electronics intends to issue convertible bonds to raise up to 330 million yuan [17] Other Developments - Xianju Pharmaceutical has obtained a domestic production registration certificate for Dydrogesterone tablets [18] - Rongchang Bio has received a clinical trial application acceptance notice for its antibody-drug conjugate RC278 [19] - Jiangsu Leili's subsidiary Dingzhi Technology is implementing a stock incentive plan [20]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-034 号 中国医药健康产业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年5月28日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一)股东大会类型和届次 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 28 日14 点 30 分 召开地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11 ...

证券代码：600056 证券简称：中国医药 公告编号：临2025-032号 中国医药健康产业股份有限公司 第九届董事会第 26 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第26次 会议（以下简称"本次会议"）于2025年5月12日以现场结合通讯方式召开，会议由 董事长杨光先生主持，公司监事及相关高级管理人员列席了本次会议。 等事宜。具体内容请详见公司在上海证券交易所网站（www.sse.com.cn）发布的临 表决结果：同意 3 票；反对 0 票；弃权 0 票。关联董事杨光、童朝银、胡慧冬 及周兴兵回避表决。 本议案尚需提交股东大会审议通过。 (三)本次会议应出席董事7名，实际出席会议董事7名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为 有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于收购金穗科技 100%股权的议案》。 本议案涉及关联交易，按照相关规定，经公 ...

重要内容提示： 证券代码：600056 证券简称：中国医药 公告编号：临2025-033号 中国医药健康产业股份有限公司 关于公司收购关联方资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国医药健康产业股份有限公司（以下简称"中国医药"或"公司"）拟 与中国新兴集团有限责任公司（以下简称"新兴集团"）及北京金穗科技开发有 限责任公司（以下简称"金穗科技"）签署《关于北京金穗科技开发有限责任公 司的100%股权转让协议》，以现金出资30,207万元收购新兴集团所持金穗科技 100%股权。 根据《上海证券交易所股票上市规则》等相关法律法规及《公司章程》等 有关规定，鉴于新兴集团系公司控股股东中国通用技术（集团）控股有限责任公 司（以下简称"通用技术集团"）的全资子公司，并持有金穗科技100%股权，新 兴集团与公司构成同一控制下的关联关系，公司与新兴集团的上述交易构成关联 交易。 本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 过去12个月内公司与关联方发生的同类关联交易包括以现金6,844万 ...

证券代码：600056 证券简称：中国医药 公告编号：临2025-032号 中国医药健康产业股份有限公司 第九届董事会第 26 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第26次 会议（以下简称"本次会议"）于2025年5月12日以现场结合通讯方式召开，会议由 董事长杨光先生主持，公司监事及相关高级管理人员列席了本次会议。 (二)本次会议通知于2025年5月7日以邮件、短信、电话或传真的方式向全体董 事发出。 （一）审议通过了《关于收购金穗科技 100%股权的议案》。 本议案涉及关联交易，按照相关规定，经公司独立董事专门会议审议，全体独 立董事一致同意将该议案提交本次会议审议。 经决议，董事会同意公司收购北京金穗科技有限公司（以下简称"金穗科技"） 100%股权、签署相关协议，以及金穗科技部分存续业务因本次收购形成的关联交易 等事宜。具体内容请详见公司在上海证券交易所网站（www.sse.com.cn）发布的临 2025- ...

्Ӣ䠇ろ〇ᢶᔶਇᴿ䲆䍙Աޢਮ ᒪ ᴾȽᒪᓜȽᒪᓜȽᒪᓜ ᇗ䇗ᣛ | ㍘ᕋ | | 享⸷ | | --- | --- | --- | | ᇗ䇗ᣛ઀ | | | | ਮ䍘ޢ | ᣛ㺞ࣗ | | | Ă | ਾᒬ䍺ӝ䍕ٰ㺞 | | | Ă | ∃ޢਮ䍺ӝ䍕ٰ㺞 | | | Ă | ਾᒬ࡟⏜㺞 | | | Ă | ∃ޢਮ࡟⏜㺞 | | | Ă | ਾᒬ⧦䠇⍷䠅㺞 | | | Ă | ∃ޢਮ⧦䠇⍷䠅㺞 | | | Ă | ਾᒬ㛗ђᵹⴀ਎ࣞ㺞 | | | Ă | ∃ޢਮ㛗ђᵹⴀ਎ࣞ㺞 | | | Ă | 䍘ࣗᣛ㺞䱺⌞ | | g ᇗ䇗ᣛ ;<=+7<$$% ेӜ䠁ょ、ᢰᔰਁᴹ䲀䍓ԫޜਨ ѝഭ५㦟ڕᓧӗъ㛑ԭᴹ䲀ޜਨǃѝഭᯠޤ䳶ഒᴹ䲀䍓ԫޜਨ˖ аǃ ᇑ䇑㿱 ᡁԜᇑ䇑ҶेӜ䠁ょ、ᢰᔰਁᴹ䲀䍓ԫޜਨ˄ԕлㆰ〠Ā䠁ょޜਨā˅䍒࣑ᣕ㺘ˈव ᤜ ᒤ ᴸ ᰕǃ ᒤ ᴸ ᰕǃ ᒤ ᴸ ᰕǃ ᒤ ᴸ ᰕⲴ ਸᒦ৺⇽ޜਨ䍴ӗ䍏٪㺘ˈ ᒤᓖ ᴸǃ ᒤᓖǃ ᒤᓖǃ ᒤᓖⲴਸᒦ ৺⇽ޜਨ࡙⏖㺘ǃਸᒦ৺⇽ޜਨ⧠䠁⍱䟿㺘ǃਸᒦ৺⇽ޜਨᡰᴹ㘵ᵳ⳺ਈࣘ㺘ˈԕ৺ ޣ䍒࣑ᣕ㺘䱴⌘DŽ ᡁԜ䇔Ѫˈਾ䱴Ⲵ䍒࣑ᣕ㺘൘ᡰᴹ䟽བྷᯩ䶒᤹➗ԱъՊ䇑߶ࡉⲴ㿴ᇊԕ৺䍒࣑ᣕ ...